{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:42:02Z","timestamp":1790797322237,"version":"4.1.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40273-025-01532-w","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T08:28:01Z","timestamp":1755505681000},"page":"1323-1338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Developing a Comprehensive Framework for Cost-Effectiveness Evaluation in Metastatic Castration-Sensitive Prostate Cancer: Insights from a Systematic Review"],"prefix":"10.1007","volume":"43","author":[{"given":"Christopher G","family":"Fawsitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Kayongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Thom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noman","family":"Paracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"1532_CR1","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10: 811044.","journal-title":"Front Public Health"},{"key":"1532_CR2","first-page":"1","volume-title":"The epidemiology of prostate cancer","author":"S Giona","year":"2021","unstructured":"Giona S. The epidemiology of prostate cancer. Brisbane: Exon Publications; 2021. p. 1\u201315."},{"key":"1532_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11934-017-0649-z","volume":"18","author":"RT Dess","year":"2017","unstructured":"Dess RT, Morgan TM, Nguyen PL, Mehra R, Sandler HM, Feng FY, et al. Adjuvant versus early salvage radiation therapy following radical prostatectomy for men with localized prostate cancer. Curr Urol Rep. 2017;18:1\u201312.","journal-title":"Curr Urol Rep"},{"issue":"17","key":"1532_CR4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA, Metcalfe C, Davis M, Turner EL, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547\u201358.","journal-title":"N Engl J Med"},{"issue":"7","key":"1532_CR5","first-page":"684","volume":"30","author":"DR Kaye","year":"2024","unstructured":"Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Lefebvre P, et al. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States. J Manag Care Spec Pharm. 2024;30(7):684\u201397.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"1532_CR6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/JU.0000000000002121","volume":"206","author":"CJ Ryan","year":"2021","unstructured":"Ryan CJ, Ke X, Lafeuille M-H, Romdhani H, Kinkead F, Lefebvre P, et al. Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States. J Urol. 2021;206(6):1420\u20139.","journal-title":"J Urol"},{"issue":"9","key":"1532_CR7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u201334.","journal-title":"Ann Oncol"},{"key":"1532_CR8","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S398129","author":"MF Meagher","year":"2023","unstructured":"Meagher MF, Salmasi A, Stewart TF. Treatment landscape for metastatic castrate-sensitive prostate cancer: a review. Res Rep Urol. 2023. https:\/\/doi.org\/10.2147\/RRU.S398129.","journal-title":"Res Rep Urol"},{"issue":"12","key":"1532_CR9","doi-asserted-by":"crossref","first-page":"S623","DOI":"10.1016\/j.jval.2024.10.3131","volume":"27","author":"T Nguyen","year":"2024","unstructured":"Nguyen T, Ameyaw D, Obeng G, Amuah R, J\u00f3zwiak-Hagym\u00e1sy J, D\u00f3czi T, et al. SA50 systematic literature review on economic evaluations and health economic models in the field of metastatic castration-sensitive prostate cancer. Value Health. 2024;27(12):S623.","journal-title":"Value Health"},{"issue":"5","key":"1532_CR10","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/curroncol29050275","volume":"29","author":"I Yanev","year":"2022","unstructured":"Yanev I, Gatete J Jr, Aprikian AG, Guertin JR, Dragomir A. The health economics of metastatic hormone-sensitive and non-metastatic castration-resistant prostate cancer\u2014a systematic literature review with application to the Canadian context. Curr Oncol. 2022;29(5):3393\u2013424.","journal-title":"Curr Oncol"},{"issue":"3","key":"1532_CR11","first-page":"E126","volume":"16","author":"A Parmar","year":"2022","unstructured":"Parmar A, Timilshina N, Emmenegger U, Smoragiewicz M, Sander B, Alibhai S, et al. A cost-utility analysis of apalutamide for metastatic castrationsensitive prostate cancer. Can Urol Assoc J. 2022;16(3):E126.","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"1532_CR12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/13696998.2022.2066850","volume":"25","author":"F Saad","year":"2022","unstructured":"Saad F, Chilelli A, Hui B, Muratov S, Ganguli A, North S, et al. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. J Med Econ. 2022;25(1):583\u201390.","journal-title":"J Med Econ"},{"key":"1532_CR13","doi-asserted-by":"publisher","unstructured":"Sathianathen NJ, Lawrentschuk N, Konety BR, Azad A, Corcoran N, Bolton DM, et al. Cost effectiveness of systemic treatment intensification for metastatic hormone-sensitive prostate cancer: is triplet therapy cost effective? Eur Urol Oncol. 2024. 7(4):870\u2013876. https:\/\/doi.org\/10.1016\/j.euo.2023.11.013. Epub 2023 Dec 6. PMID: 38057191","DOI":"10.1016\/j.euo.2023.11.013"},{"issue":"6","key":"1532_CR14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.euo.2018.06.004","volume":"1","author":"BS Woods","year":"2018","unstructured":"Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MKB, Alzouebi M, et al. Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): modelling to estimate long-term survival, quality-adjusted survival, and cost-effectiveness. Eur Urol Oncol. 2018;1(6):449\u201358.","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"1532_CR15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.5489\/cuaj.5889","volume":"13","author":"J Beca","year":"2019","unstructured":"Beca J, Majeed H, Chan KKW, Hotte SJ, Loblaw A, Hoch JS. Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer. Can Urol Assoc J. 2019;13(12):396\u2013403.","journal-title":"Can Urol Assoc J"},{"issue":"5","key":"1532_CR16","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/j.clgc.2021.03.022","volume":"19","author":"R Pelloux-Prayer","year":"2021","unstructured":"Pelloux-Prayer R, Schiele P, Oudard S, Gravis G, Kleinclauss F, Crehange G, et al. Cost-effectiveness analysis of innovative therapy for patients with newly diagnosed hormone-sensitive metastatic prostate cancer. Clin Genitourin Cancer. 2021;19(5):e326\u201333.","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"1532_CR17","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jnci\/djad135","volume":"115","author":"M Yoo","year":"2023","unstructured":"Yoo M, Nelson R, Haaland B, Dougherty M, Cutshall Z, Kohli R, et al. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective. J Natl Cancer Inst. 2023;115(11):1374\u201382.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1532_CR18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jval.2017.09.022","volume":"21","author":"F Pan","year":"2018","unstructured":"Pan F, Reifsnider O, Zheng Y, Proskorovsky I, Li T, He J, et al. Modeling clinical outcomes in prostate cancer: application and validation of the discrete event simulation approach. Value Health. 2018;21(4):416\u201322.","journal-title":"Value Health"},{"issue":"12","key":"1532_CR19","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","volume":"23","author":"BS Woods","year":"2020","unstructured":"Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1613\u201321.","journal-title":"Value Health"},{"issue":"7","key":"1532_CR20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41416-022-01904-5","volume":"127","author":"LC Cheung","year":"2022","unstructured":"Cheung LC, Albert PS, Das S, Cook RJ. Multistate models for the natural history of cancer progression. Br J Cancer. 2022;127(7):1279\u201388.","journal-title":"Br J Cancer"},{"key":"1532_CR21","volume-title":"Competing risks and multistate models with R","author":"J Beyersmann","year":"2011","unstructured":"Beyersmann J, Allignol A, Schumacher M. Competing risks and multistate models with R. Berlin: Springer Science & Business Media; 2011."},{"issue":"4","key":"1532_CR22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0272989X16651869","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: a tutorial. Med Decis Mak. 2017;37(4):340\u201352.","journal-title":"Med Decis Mak"},{"issue":"10","key":"1532_CR23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1080\/13696998.2020.1796360","volume":"23","author":"H Cranmer","year":"2020","unstructured":"Cranmer H, Shields GE, Bullement A. A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. J Med Econ. 2020;23(10):1176\u201385.","journal-title":"J Med Econ"},{"issue":"4","key":"1532_CR24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling. Med Decis Mak. 2017;37(4):427\u201339.","journal-title":"Med Decis Mak"},{"issue":"4","key":"1532_CR25","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0272989X11406986","volume":"31","author":"CH Jackson","year":"2011","unstructured":"Jackson CH, Bojke L, Thompson SG, Claxton K, Sharples LD. A framework for addressing structural uncertainty in decision models. Med Decis Mak. 2011;31(4):662\u201374.","journal-title":"Med Decis Mak"},{"issue":"9","key":"1532_CR26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40273-017-0501-9","volume":"35","author":"H Thom","year":"2017","unstructured":"Thom H, Jackson C, Welton N, Sharples L. Using parameter constraints to choose state structures in cost-effectiveness modelling. Pharmacoeconomics. 2017;35(9):951\u201362.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1532_CR27","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40273-020-00941-3","volume":"38","author":"S Lopes","year":"2020","unstructured":"Lopes S, Johansen P, Lamotte M, McEwan P, Olivieri AV, Foos V. External validation of the core obesity model to assess the cost-effectiveness of weight management interventions. Pharmacoeconomics. 2020;38(10):1123\u201333.","journal-title":"Pharmacoeconomics"},{"key":"1532_CR28","doi-asserted-by":"crossref","unstructured":"Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. NIHR Health Technology Assessment Programme: Executive Summaries. 2011.","DOI":"10.3310\/hta15100"},{"key":"1532_CR29","unstructured":"NICE. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene; HST22: National Institute for Health and Care Excellence. 2023 [cited 14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/hst22. Accessed 14 Mar 2025."},{"key":"1532_CR30","unstructured":"NICE. Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over; TA103: National Institute for Health and Care Excellence. 2025 14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/ta1031. Accessed 14 Mar 2025."},{"key":"1532_CR31","volume":"22","author":"F Woodcock","year":"2019","unstructured":"Woodcock F, Mumby-Croft J, Ghosh S, Chandler F, Godfrey J, Crossley E. PRO16 project Hercules: a case study in developing a multi-company, flexible cost-effectiveness model in a rare disease. Value Health. 2019;22: S843.","journal-title":"Value Health"},{"key":"1532_CR32","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1016\/j.jval.2019.09.2351","volume":"22","author":"F Woodcock","year":"2019","unstructured":"Woodcock F, Mumby-Croft J, Ghosh S, Chandler F, Godfrey J, Crossley E. PRO20 project hercules: a paradigm shift in the development of cost-effectiveness models in rare diseases. Value Health. 2019;22:S844.","journal-title":"Value Health."},{"key":"1532_CR33","unstructured":"NICE. Dimethyl fumarate for treating relapsing\u2011remitting multiple sclerosis; TA320: National Institute for Health and Care Excellence. 2014 [14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/ta320. Accessed 14 Mar 2025."},{"key":"1532_CR34","unstructured":"NICE. Teriflunomide for treating relapsing\u2013remitting multiple sclerosis; TA303: National Institute for Health and Care Excellence. 2014 [14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/ta303. Accessed 14 Mar 2025."},{"key":"1532_CR35","unstructured":"NICE. Ozanimod for treating relapsing\u2013remitting multiple sclerosis; TA706: National Institute for Health and Care Excellence. 2021 [14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/ta706. Accessed 14 Mar 2025."},{"issue":"12","key":"1532_CR36","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40273-019-00822-4","volume":"37","author":"M Laxy","year":"2019","unstructured":"Laxy M, Sch\u00f6ning VM, Kurz C, Holle R, Peters A, Meisinger C, et al. Performance of the UKPDS outcomes model 2 for predicting death and cardiovascular events in patients with type 2 diabetes mellitus from a German population-based cohort. Pharmacoeconomics. 2019;37(12):1485\u201394.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1532_CR37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jval.2021.09.005","volume":"25","author":"MJ Keng","year":"2022","unstructured":"Keng MJ, Leal J, Mafham M, Bowman L, Armitage J, Mihaylova B. Performance of the UK prospective diabetes study outcomes model 2 in a contemporary UK type 2 diabetes trial cohort. Value Health. 2022;25(3):435\u201342.","journal-title":"Value Health"},{"key":"1532_CR38","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray A, Holman R, Clarke P. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study: UKPDS 82. Diabetologia. 2013;56:1925\u201333.","journal-title":"Diabetologia"},{"key":"1532_CR39","unstructured":"NICE. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus; TA151: National Institute for Health and Care Excellence. 2008 [14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/ta151. Accessed 14 Mar 2025."},{"key":"1532_CR40","unstructured":"NICE. Type 2 diabetes prevention: population and community-level interventions; PH35: National Institute for Health and Care Excellence. 2011 [14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/ph35. Accessed 14 Mar 2025."},{"key":"1532_CR41","unstructured":"NICE. Dapagliflozin in triple therapy for treating type 2 diabetes; TA418: National Institute for Health and Care Excellence. 2016 [14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/ta418. Accessed 14 Mar 2025."},{"key":"1532_CR42","unstructured":"NICE. Dapagliflozin in combination therapy for treating type 2 diabetes; TA288: National Institute for Health and Care Excellence. 2013 [14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/ta288. Accessed 14 Mar 2025."},{"issue":"1","key":"1532_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40273-018-0711-9","volume":"37","author":"S Ghabri","year":"2019","unstructured":"Ghabri S, Stevenson M, M\u00f6ller J, Caro JJ. Trusting the results of model-based economic analyses: is there a pragmatic validation solution? Pharmacoeconomics. 2019;37(1):1\u20136.","journal-title":"Pharmacoeconomics"},{"key":"1532_CR44","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli NC, Rutten-van M\u00f6lken MP, Severens JL, Al M. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37:1391\u2013408.","journal-title":"Pharmacoeconomics"},{"issue":"7052","key":"1532_CR45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"M Drummond","year":"1996","unstructured":"Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ Br Med J. 1996;313(7052):275.","journal-title":"BMJ Br Med J."},{"key":"1532_CR46","unstructured":"Initiative IM. Prostate cancer diagnosis and treatment enhancement through the power of big data in Europe PIONEER. D6.2 Prostate cancer reference models. 2023. https:\/\/prostate-pioneer.eu\/wpcontent\/uploads\/2024\/01\/PIONEER_Deliverable-6.2_pdf"},{"issue":"5","key":"1532_CR47","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Mak. 2012;32(5):667\u201377.","journal-title":"Med Decis Mak"},{"issue":"5","key":"1532_CR48","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0272989X12454941","volume":"32","author":"M Roberts","year":"2012","unstructured":"Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Med Decis Mak. 2012;32(5):678\u201389.","journal-title":"Med Decis Mak"},{"issue":"6","key":"1532_CR49","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jval.2012.06.011","volume":"15","author":"R Pitman","year":"2012","unstructured":"Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force-5. Value Health. 2012;15(6):828\u201334.","journal-title":"Value Health"},{"issue":"5","key":"1532_CR50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/0272989X12455462","volume":"32","author":"J Karnon","year":"2012","unstructured":"Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, M\u00f6ller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force-4. Med Decis Mak. 2012;32(5):701\u201311.","journal-title":"Med Decis Mak"},{"issue":"5","key":"1532_CR51","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","volume":"32","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Med Decis Mak. 2012;32(5):690\u2013700.","journal-title":"Med Decis Mak"},{"key":"1532_CR52","unstructured":"Canada Drug Agency. Model Validation Tool. 2024 [cited 2024].https:\/\/www.cda-amc.ca\/model-validation-tool. Accessed 15 Dec 2024."},{"key":"1532_CR53","unstructured":"Pharmaceutical Benefits Advisory Committee Guidelines. Model validation. 2016 [cited 2024]. https:\/\/pbac.pbs.gov.au\/section-3a\/3a-7-model-validation.html. Accessed 15 Dec 2024."},{"key":"1532_CR54","unstructured":"NICE. NICE health technology evaluations: the manual. 2023 [cited 2024]. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2. Accessed 15 Dec 2024."},{"key":"1532_CR55","volume":"372","author":"M Page","year":"2021","unstructured":"Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"issue":"9","key":"1532_CR56","first-page":"E418","volume":"14","author":"AE Hird","year":"2020","unstructured":"Hird AE, Magee DE, Cheung DC, Matta R, Kulkarni GS, Nam RK. Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: a microsimulation model. Can Urol Assoc J. 2020;14(9):E418\u201327.","journal-title":"Can Urol Assoc J"},{"issue":"12","key":"1532_CR57","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.jval.2024.10.538","volume":"27","author":"J Fragoso","year":"2024","unstructured":"Fragoso J, Pereira P, Valente C, Andr\u00e9 S. EE256 darolutamide as a leading option to manage prostate cancer. Value Health. 2024;27(12):S104.","journal-title":"Value Health"},{"issue":"11","key":"1532_CR58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277282","volume":"17","author":"M Barbier","year":"2022","unstructured":"Barbier M, Tomonaga Y, Menges D, Henock Y, Haile S, Puhan M, et al. Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer. PLoS ONE. 2022;17(11): e0277282.","journal-title":"PLoS ONE"},{"issue":"3","key":"1532_CR59","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.japh.2022.12.019","volume":"63","author":"O Adekunle","year":"2023","unstructured":"Adekunle O, Seoane-Vazquez E, Brown L. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer. J Am Pharm Assoc. 2023;63(3):817-24.e3.","journal-title":"J Am Pharm Assoc"},{"issue":"6 Supplement","key":"1532_CR60","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.jval.2023.03.353","volume":"26","author":"A Katta","year":"2023","unstructured":"Katta A, Hansen R. Cost-effectiveness of abiraterone, enzalutamide, and apalutamide in metastatic castration-sensitive prostate cancer (MCSPC): a partitioned-survival model. Value Health. 2023;26(6 Supplement):S68.","journal-title":"Value Health"},{"key":"1532_CR61","doi-asserted-by":"crossref","unstructured":"Naqvi SAA, Faisal KS, Khan MA, Khakwani KZR, Van Houten HK, Moriarty JP, et al. A cost-effectiveness analysis assessing systemic treatments in metastatic castration-sensitive prostate cancer (mCSPC) by volume of disease. Alexandria: American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.4_suppl.93"},{"issue":"6 Supplement","key":"1532_CR62","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jval.2023.03.562","volume":"26","author":"I Nwogu","year":"2023","unstructured":"Nwogu I, Nedzesky J, Carlson J. EE261 cost-effectiveness of adding darolutamide to docetaxel and androgen deprivation therapy in the treatment of metastatic hormone-sensitive prostrate cancer. Value Health. 2023;26(6 Supplement):S106.","journal-title":"Value Health"},{"key":"1532_CR63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.222","author":"NH Lester-Coll","year":"2024","unstructured":"Lester-Coll NH, Benjamin DJ, Ribault H, Foulon S, Fizazi K, Rezazadeh A, American Society of Clinical Oncology. Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.222.","journal-title":"J Clin Oncol"},{"issue":"7 Supplement","key":"1532_CR64","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1016\/j.jval.2022.04.459","volume":"25","author":"B Jiao","year":"2022","unstructured":"Jiao B, Carlson J, Garrison L, Nyame Y, Base A. EE210 value of expanding first-line treatment choices: new metrics for economic evaluation. Value Health. 2022;25(7 Supplement):S374\u20135.","journal-title":"Value Health"},{"issue":"5","key":"1532_CR65","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2021.10.016","volume":"25","author":"L Wang","year":"2022","unstructured":"Wang L, Hong H, Alexander GC, Brawley O, Paller C, Ballreich J. Cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: an economic evaluation based on network meta-analysis. Value Health. 2022;25(5):796\u2013802.","journal-title":"Value Health"},{"key":"1532_CR66","volume":"11","author":"WW Sung","year":"2021","unstructured":"Sung WW, Choi HC, Luk PH, So TH. A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer. Front Oncol. 2021;11: 627083.","journal-title":"Front Oncol"},{"key":"1532_CR67","volume":"9","author":"PF Zhang","year":"2021","unstructured":"Zhang PF, Xie D, Li Q. Adding enzalutamide to first-line treatment for metastatic hormone-sensitive prostate cancer: a cost-effectiveness analysis. Front Public Health. 2021;9: 608375.","journal-title":"Front Public Health"},{"issue":"4","key":"1532_CR68","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ijrobp.2020.06.009","volume":"108","author":"NR Parikh","year":"2020","unstructured":"Parikh NR, Chang EM, Nickols NG, Rettig MB, Raldow AC, Steinberg ML, et al. Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer. Int J Radiat Oncol Biol Phys. 2020;108(4):917\u201326.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"1532_CR69","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.urolonc.2019.05.017","volume":"37","author":"C Ramamurthy","year":"2019","unstructured":"Ramamurthy C, Handorf EA, Correa AF, Beck JR, Geynisman DM. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone na\u00efve prostate cancer. Urol Oncol. 2019;37(10):688\u201395.","journal-title":"Urol Oncol"},{"issue":"6","key":"1532_CR70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269192","volume":"17","author":"C Clarke","year":"2022","unstructured":"Clarke C, Hunter R, Gabrio A, Brawley C, Ingleby F, Dearnaley DP, et al. Cost-utility analysis of adding abiraterone acetate + prednisone\/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: lifetime decision model based on STAMPEDE trial data. PLoS ONE. 2022;17(6): e0269192.","journal-title":"PLoS ONE"},{"issue":"8","key":"1532_CR71","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1464-410X.2011.10434.x","volume":"109","author":"L Lu","year":"2012","unstructured":"Lu L, Peters J, Roome C, Stein K. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 2012;109(8):1183\u201392.","journal-title":"BJU Int"},{"issue":"12","key":"1532_CR72","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.jval.2023.09.1841","volume":"26","author":"O Madani","year":"2023","unstructured":"Madani O. HTA157 reflection on medicines that have recently come off patent and have been rejected by NICE in the past 20 years: a case study of abiraterone for treating newly diagnosed metastatic hormone sensitive prostate cancer (MHSPC). Value Health. 2023;26(12):S349.","journal-title":"Value Health"},{"key":"1532_CR73","unstructured":"PC0294-000 CD. Darolutamide In combination with docetaxel for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) in patients who are chemotherapy-eligible. 2023 [9 April 2024]. https:\/\/www.cadth.ca\/darolutamide. Accessed 9 Apr 2024."},{"key":"1532_CR74","unstructured":"PC0200-000 CA. Apalutamide in metastatic castration-sensitive prostate cancer (mCSPC). 2020 [9 April 2024]. https:\/\/www.cadth.ca\/apalutamide-erleada-metastatic-castration-sensitive-prostate-cancer-details. Accessed 9 Apr 2024."},{"key":"1532_CR75","unstructured":"PC0209-000 CE. Enzalutamide (Xtandi\u00ae) for metastatic hormone sensitive prostate cancer. 2020 [9 April 2024]. https:\/\/www.cadth.ca\/enzalutamide-xtandi-metastatic-castration-sensitive-prostate-cancer-details. Accessed 9 Apr 2024.."},{"key":"1532_CR76","unstructured":"SMC2604 SD. Darolutamide (Nubeqa) treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel. 2023 [9 April 2024]. https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/darolutamide-nubeqa-ft-resub-smc2604\/Accessed 9 Apr 2024.."},{"key":"1532_CR77","unstructured":"SMC2472 SA. Apalutamide (Erleada) In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). 2022 [9 April 2024]. https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/apalutamide-erleada-full-smc2472\/. Accessed 9 Apr 2024."},{"key":"1532_CR78","unstructured":"SMC2400 SE. Enzalutamide (Xtandi) For treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy. 2022 [9 April 2024]. https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/enzalutamide-xtandi-full-smc2400\/. Accessed 9 Apr 2024."},{"key":"1532_CR79","unstructured":"SMC [Abiraterone]. Abiraterone acetate 500mg film-coated tablets (Zytiga\u00ae). 2019 [10 February 2022]. https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/abiraterone-acetate-zytiga-full-smc2215\/. Accessed 9 Apr 2024."},{"key":"1532_CR80","unstructured":"NICE. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer; TA903: National Institute for Health and Care Excellence. 2023 [9 April 2024]. https:\/\/www.nice.org.uk\/guidance\/ta903\/history. Accessed 9 Apr 2024."},{"key":"1532_CR81","unstructured":"NICE. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer; TA721: National Institute for Health and Care Excellence. 2021 [9 April 2024]. https:\/\/www.nice.org.uk\/guidance\/ta721\/history. Accessed 9 Apr 2024."},{"key":"1532_CR82","unstructured":"NICE. Enzalutamide for treating hormone-sensitive metastatic prostate cancer; TA712: National Institute for Health and Care Excellence. 2021 [10 February 2022]. https:\/\/www.nice.org.uk\/guidance\/ta712. Accessed 9 Apr 2024."},{"key":"1532_CR83","unstructured":"NICE. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer; TA741: National Institute for Health and Care Excellence. NICE 2021 10 February 2020 [10 February 2022]. https:\/\/www.nice.org.uk\/guidance\/ta741. Accessed 9 Apr 2024."},{"key":"1532_CR84","unstructured":"NICE. Relugolix for treating hormone-sensitive prostate cancer; TA995: National Institute for Health and Care Excellence. 2024 [14 March 2025]. https:\/\/www.nice.org.uk\/guidance\/ta995. Accessed 14 Mar 2025."},{"key":"1532_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-019-0182-7","volume":"17","author":"MA Pahuta","year":"2019","unstructured":"Pahuta MA, Werier J, Wai EK, Patchell RA, Coyle D. A technique for approximating transition rates from published survival analyses. Cost Eff Resour Alloc. 2019;17:1\u20138.","journal-title":"Cost Eff Resour Alloc"},{"issue":"19","key":"1532_CR86","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/sim.9810","volume":"42","author":"JP Jansen","year":"2023","unstructured":"Jansen JP, Incerti D, Trikalinos TA. Multi-state network meta-analysis of progression and survival data. Stat Med. 2023;42(19):3371\u201391.","journal-title":"Stat Med"},{"key":"1532_CR87","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The statistical analysis of failure time data","author":"JD Kalbfleisch","year":"2002","unstructured":"Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 2002."},{"issue":"1","key":"1532_CR88","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0272989X221121747","volume":"43","author":"F Alarid-Escudero","year":"2023","unstructured":"Alarid-Escudero F, Krijkamp E, Enns EA, Yang A, Hunink MM, Pechlivanoglou P, et al. A tutorial on time-dependent cohort state-transition models in R using a cost-effectiveness analysis example. Med Decis Mak. 2023;43(1):21\u201341.","journal-title":"Med Decis Mak"},{"key":"1532_CR89","unstructured":"Incerti D, Jansen JP. hesim: Health economic simulation modeling and decision analysis. arXiv preprint arXiv:210209437. 2021."},{"issue":"12","key":"1532_CR90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"1","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol. 2012;1(12):9.","journal-title":"BMC Med Res Methodol"},{"key":"1532_CR91","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-021-01460-1","volume":"21","author":"B Kearns","year":"2021","unstructured":"Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A. Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study. BMC Med Res Methodol. 2021;21: 1\u201311.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"1532_CR92","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.urpr.2015.06.008","volume":"3","author":"A Weinberg","year":"2016","unstructured":"Weinberg A, Liu J, Sandelien M, Waite N, Reese J. Epididymal sparing bilateral simple orchiectomy: cost-effectiveness and aesthetic preservation for men with metastatic prostate cancer. Urol Pract. 2016;3(2):112\u20137.","journal-title":"Urol Pract"},{"issue":"9","key":"1532_CR93","volume":"151","author":"S Stoffel","year":"2021","unstructured":"Stoffel S, von Moos R, Thurlimann B, Cathomas R, Gillessen S, Zurrer-Hardi U, et al. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland\u2014the SAKK 95\/16 prostate study. Swiss Med Wkly. 2021;151(9): w20464.","journal-title":"Swiss Med Wkly"},{"issue":"2","key":"1532_CR94","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","volume":"19","author":"KN Chi","year":"2018","unstructured":"Chi KN, Protheroe A, Rodr\u00edguez-Antol\u00edn A, Facchini G, Suttman H, Matsubara N, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol. 2018;19(2):194\u2013206.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1532_CR95","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa1201637","volume":"367","author":"EA Heijnsdijk","year":"2012","unstructured":"Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012;367(7):595\u2013605.","journal-title":"N Engl J Med"},{"issue":"11","key":"1532_CR96","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","volume":"36","author":"AK Morgans","year":"2018","unstructured":"Morgans AK, Chen Y-H, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, et al. Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer. J Clin Oncol. 2018;36(11):1088\u201395.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1532_CR97","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","volume":"2","author":"NJ Sathianathen","year":"2019","unstructured":"Sathianathen NJ, Alarid-Escudero F, Kuntz KM, Lawrentschuk N, Bolton DM, Murphy DG, et al. A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer. Eur Urol Oncol. 2019;2(6):649\u201355.","journal-title":"Eur Urol Oncol"},{"issue":"21","key":"1532_CR98","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jnci\/92.21.1731","volume":"92","author":"AM Bayoumi","year":"2000","unstructured":"Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst. 2000;92(21):1731\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1532_CR99","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s11136-019-02117-9","volume":"28","author":"F Hall","year":"2019","unstructured":"Hall F, de Freitas HM, Kerr C, Ito T, Nafees B, Lloyd AJ, et al. Estimating utilities\/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. Qual Life Res. 2019;28(5):1191\u20139.","journal-title":"Qual Life Res"},{"issue":"11","key":"1532_CR100","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/cer-2018-0133","volume":"8","author":"M Liu","year":"2019","unstructured":"Liu M, Qu S, Liu Y, Yao X, Jiang W. Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China. J Comp Eff Res. 2019;8(11):865\u201377.","journal-title":"J Comp Eff Res"},{"key":"1532_CR101","doi-asserted-by":"crossref","unstructured":"Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol Assess (Winchester, Engl). 2007;11(2):iii-iv, xv.","DOI":"10.3310\/hta11020"},{"key":"1532_CR102","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11136-014-0794-5","volume":"24","author":"J Diels","year":"2015","unstructured":"Diels J, Hamberg P, Ford D, Price PW, Spencer M, Dass R. Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. Qual Life Res. 2015;24:591\u20138.","journal-title":"Qual Life Res"},{"key":"1532_CR103","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.08.010","volume":"103","author":"S Feyerabend","year":"2018","unstructured":"Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S, et al. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur J Cancer. 2018;103:78\u201387.","journal-title":"Eur J Cancer"},{"issue":"10336","key":"1532_CR104","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399(10336):1695\u2013707.","journal-title":"Lancet"},{"issue":"4","key":"1532_CR105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"1532_CR106","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00005650-200301000-00017","volume":"41","author":"M Krahn","year":"2003","unstructured":"Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41(1):153\u201364.","journal-title":"Med Care"},{"issue":"11","key":"1532_CR107","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen Y-H, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080\u20137.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1532_CR108","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187\u201396.","journal-title":"N Engl J Med"},{"issue":"4","key":"1532_CR109","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.mlr.0000156862.33341.45","volume":"43","author":"ST Stewart","year":"2005","unstructured":"Stewart ST, Lenert L, Bhatnagar V, Kaplan RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43(4):347\u201355.","journal-title":"Med Care"},{"issue":"4","key":"1532_CR110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(4):323\u201334.","journal-title":"Lancet Oncol"},{"key":"1532_CR111","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1525-1497.2004.30046.x","volume":"19","author":"RJ Volk","year":"2004","unstructured":"Volk RJ, Cantor SB, Cass AR, Spann SJ, Weller SC, Krahn MD. Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. J Gen Intern Med. 2004;19:339\u201348.","journal-title":"J Gen Intern Med"},{"issue":"5","key":"1532_CR112","volume":"8","author":"L Zhong","year":"2013","unstructured":"Zhong L, Pon V, Srinivas S, Nguyen N, Frear M, Kwon S, et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS ONE. 2013;8(5): e64275.","journal-title":"PLoS ONE"},{"key":"1532_CR113","unstructured":"NICE. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated; TA387: National Institute for Health and Care Excellence. 2016 [6 February 2025]. https:\/\/www.nice.org.uk\/guidance\/ta387. Accessed 14 Mar 2025."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01532-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01532-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01532-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:42:58Z","timestamp":1760715778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01532-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":113,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01532-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"3 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was funded by Bayer Pharmaceuticals AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"E.G. and N.P. are the employees of Bayer Pharmaceuticals AG. A.S., H.B., H.T., E.K., and C.F. were paid consultants to Bayer Pharmaceuticals AG.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the drafting and editing of the manuscript. E.G., N.P., H.T., E.K. and C.F. contributed to the conceptual modelling framework, and A.S., E.G. and N.P. contributed to the systematic review. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}